Roivant Sciences CEO Matt Gline has announced the acquisition of an experimental drug called mosliciguat from Bayer for the treatment of certain types of pulmonary hypertension. Roivant paid $14 million upfront to Bayer for global rights to the drug and may pay an additional $280 million in milestone-based payments, plus royalties on sales. This move comes after months of speculation from investors about how Roivant would use the $6 billion earned from the Roche deal. The drug will be developed to treat serious lung diseases where high blood pressure affects the arteries in the lungs, causing damage to the heart.
Source link
Roivant acquires drug for pulmonary hypertension from Bayer
